Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma - Takeaways - MDSpire

Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma

  • By

  • Mitchell Pitlick

  • Mrunal K. Dehankar

  • Chantal E. McCabe

  • Sergio E. Chiarella

  • Kathleen Bartemes

  • Kay A. Bachman

  • Chung-Il Wi

  • Young J. Juhn

  • Thanai Pongdee

  • June 15, 2026

  • 0 min

Share

  • 1

    The study evaluated blood transcriptome changes in severe eosinophilic asthma patients undergoing mepolizumab therapy.

  • 2

    Fourteen patients provided sequential blood samples at baseline and weeks 4, 8, and 12 post-mepolizumab initiation.

  • 3

    At week 12, 149 genes showed significant differential expression compared to baseline, with 74 genes downregulated over time.

  • 4

    Twenty-eight genes were associated with therapy response, while 56 protein-coding genes distinguished responders from nonresponders.

  • 5

    The study concluded that mepolizumab therapy led to limited transcriptomic changes, necessitating further research for predictive markers.

Original Source(s)

Exploratory investigation of changes in blood transcriptome following mepolizumab treatment for asthma

  • by Mitchell Pitlick, Mrunal K. Dehankar, Chantal E. McCabe, Sergio E. Chiarella, Kathleen Bartemes, Kay A. Bachman, Chung-Il Wi, Young J. Juhn, Thanai Pongdee

  • June 15, 2026

Related Content

miRNA profiling shows shared signatures in pediatric asthma, obesity and their comorbidity

Relapsing allergic bronchopulmonary aspergillosis as a trigger for Kounis syndrome: a case report

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing